Skip to main content

BGI Bid to Acquire Complete Genomics Passes US Antitrust Hurdle; Tender Offer Extended Again

NEW YORK (GenomeWeb News) – BGI-Shenzhen and Complete Genomics said today that their proposed merger has cleared US antitrust review.

The companies said that they have received early termination of the Hart-Scott-Rodino waiting period from the Federal Trade Commission regarding BGI's $118 million bid for Complete.

The news comes one week after the Committee on Foreign Investment in the United States cleared the proposed acquisition.

BGI also said today that it has extended its tender offer for Complete's shares to midnight EST on Jan 11. The offer had originally been scheduled to expire on Dec. 31, 2012, and was later extended to expire at midnight today.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.